Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy Review
| Authors: | Morris, E. C.; Neelapu, S. S.; Giavridis, T.; Sadelain, M. |
| Review Title: | Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy |
| Abstract: | A paradigm shift has recently occurred in the field of cancer therapeutics. Traditional anticancer agents, such as chemotherapy, radiotherapy and small-molecule drugs targeting specific signalling pathways, have been joined by cellular immunotherapies based on T cell engineering. The rapid adoption of novel, patient-specific cellular therapies builds on scientific developments in tumour immunology, genetic engineering and cell manufacturing, best illustrated by the curative potential of chimeric antigen receptor (CAR) T cell therapy targeting CD19-expressing malignancies. However, the clinical benefit observed in many patients may come at a cost. In up to one-third of patients, significant toxicities occur that are directly associated with the induction of powerful immune effector responses. The most frequently observed immune-mediated toxicities are cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. This Review discusses our current understanding of their pathophysiology and clinical features, as well as the development of novel therapeutics for their prevention and/or management. © 2021, Springer Nature Limited. |
| Journal Title: | Nature Reviews Immunology |
| Volume: | 22 |
| Issue: | 2 |
| ISSN: | 1474-1733 |
| Publisher: | Nature Publishing Group |
| Date Published: | 2022-02-01 |
| Start Page: | 85 |
| End Page: | 96 |
| Language: | English |
| DOI: | 10.1038/s41577-021-00547-6 |
| PUBMED: | 34002066 |
| PROVIDER: | scopus |
| PMCID: | PMC8127450 |
| DOI/URL: | |
| Notes: | Review -- Export Date: 1 March 2022 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work